Tecentriq
Pharmacokinetics May Help Optimize Dosing of ICIs
Flat and extended-interval dosing of some immune checkpoint inhibitor (ICI) drugs can be used in certain ...
APRIL 14, 2022
FDA Approves Tecentriq as Adjuvant Rx for Stage II-IIIA NSCLC
The FDA approved atezolizumab (Tecentriq, Genentech) for adjuvant treatment after resection and platinum-based ...
OCTOBER 29, 2021
Tecentriq Combo Approved for First-Line Rx of Metastatic Nonsquamous NSCLC
The FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin, Genentech), ...
DECEMBER 19, 2018
FDA Modifies Indications of Pembrolizumab, Atezolizumab
The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are ...
JULY 3, 2018
FDA Warns of Decreased Survival in Some UC Patients on Keytruda or Tecentriq
The FDA issued an alert about decreased survival associated with the use of pembrolizumab (Keytruda, Merck) or ...
MAY 21, 2018
